Tango Therapeutics TNGX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $6.19M-15.2% | $5.63M-28.6% | $5.76M-30.7% | $6.48M-22.7% | $7.31M-5.8% | ||
| $56.99M+39.0% | $62.38M+48.3% | $66.5M+53.3% | $24.3M-42.8% | $40.99M+10.1% | ||
| $129.26M-9.2% | $132.17M-8.2% | $134M-5.2% | $136.45M+0.9% | $142.3M+13.6% | ||
| $174.52M-6.6% | $173.67M-7.5% | $176.84M-3.4% | $181.58M+3.8% | $186.86M+14.4% | ||
| $10.27M-25.6% | $9.7M-37.4% | $9.93M-39.9% | $11.89M-26.3% | $13.81M-5.8% | ||
| -$107.23M+18.9% | -$101.59M+22.0% | -$100.52M+18.5% | -$145.57M-25.0% | -$132.26M-18.5% | ||
| -188.2%+135pp | -162.9%+147pp | -151.1%+133pp | -599.1%-325pp | -322.7%-22.8pp | ||
| -$115.41M+19.5% | -$109.01M+23.8% | -$107.91M+21.3% | -$154.8M-19.1% | -$143.37M-15.9% | ||
| -202.5%+147pp | -174.7%+165pp | -162.3%+154pp | -637.1%-331pp | -349.8%-17.6pp | ||
| -$117.53M+19.4% | -$111.29M+23.6% | -$110.34M+21.0% | -$157.29M-18.8% | -$145.87M-15.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Tango Therapeutics's income statement data come from?
- Every line is extracted from Tango Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.